Classement en actions
#13779
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Capitalisation boursière
$458.19M
Changement (1 jour)
-3.26%
Échange Evommune, Inc. (EVMN)
Le prix EVMN avec la capitalisation boursière de B
Capitalisation boursière de Evommune, Inc.(EVMN)
Capitalisation boursière: $458.19M
En August 2026, Evommune, Inc. a une capitalisation boursière de $458.19M. Cela fait de Evommune, Inc. la 13779th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Evommune, Inc. du 2025 au 2026
EVMN par rapport au top 5 des plus populaires stocks
| Prix pour EVMN |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.327T
|
+1,162,480.60%
|
|
|
|
|
$4.632T
|
+1,010,918.15%
|
|
|
|
|
$4.062T
|
+886,437.60%
|
|
|
|
|
$3.796T
|
+828,408.76%
|
|
|
|
|
$2.781T
|
+606,898.68%
|
